Pfizer Pipeline Update Highlights 85 New Molecular Entities, 14 New Claims
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer will resubmit the NDA for its next-generation selective estrogen receptor modulator lasofoxifene in December with new data, the drug maker said in a pipeline update released Aug. 6